Approximately 10 percent of all medicines found in low- and middle-income countries are either substandard or falsified, ranging from cancer drugs and contraceptives to antibiotics and anti-malarial treatments. And the problem is almost evenly split between patented brand-name drugs and generics, according to new reports from the World Health Organization.

Moreover, the agency maintained there is a tremendous cost – about $30 billion is spent on such medicines.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The same companies that oppose imports also opposed serialization for years, which was to keep the US supply chain safe. Amazingly selective attention … as well as blindness to the falsified meds in the US supply chain already, ‘both domestic and imported.’

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy